Akèy › Skleroz Miltip
Etid klinik pou Skleroz Miltip ap rekrite nan Etazini
131 etid pou Skleroz Miltip ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- New York City, NY17 etid
- Chicago, IL15 etid
- Boston, MA14 etid
- Washington, DC13 etid
- Cleveland, OH9 etid
- Kansas City, KS8 etid
- St. Louis, MO8 etid
- Birmingham, AL8 etid
- San Francisco, CA8 etid
- Aurora, CO7 etid
- Columbus, OH7 etid
- Baltimore, MD7 etid
- Houston, TX6 etid
- Seattle, WA6 etid
- Milwaukee, WI6 etid
- Dallas, TX6 etid
- Farmington Hills, MI6 etid
- Austin, TX5 etid
- San Diego, CA5 etid
- Atlanta, GA5 etid
- Tampa, FL5 etid
- Durham, NC4 etid
- Ann Arbor, MI4 etid
- Knoxville, TN4 etid
- Naples, FL4 etid
- Orlando, FL4 etid
- Scottsdale, AZ4 etid
- Champaign, IL4 etid
- Brockton, MA4 etid
- Miami, FL4 etid
- New Haven, CT4 etid
- Cincinnati, OH3 etid
- Rochester, MN3 etid
- Gainesville, FL3 etid
- Newark, NJ3 etid
- El Paso, TX3 etid
- Raleigh, NC3 etid
- Plano, TX3 etid
- Burbank, CA3 etid
- Palm Coast, FL3 etid
Pa eta
- Alabama8 etid
- Arizona6 etid
- Ayiti3 etid
- Colorado11 etid
- Connecticut6 etid
- Distrik Columbia4 etid
- Florid14 etid
- Georgia7 etid
- Illinois19 etid
- Kalifòni24 etid
- Kansas9 etid
- Kentucky3 etid
- Maryland17 etid
- Massachusetts18 etid
- Michigan10 etid
- Minnesota4 etid
- Missouri8 etid
- Nebraska3 etid
- New Jersey11 etid
- New York19 etid
- North Carolina8 etid
- Ohio14 etid
- Oklahoma3 etid
- Pennsylvania7 etid
- Tennessee6 etid
- Texas17 etid
- Utah3 etid
- Virginia3 etid
- Washington10 etid
- Wisconsin7 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
Ap rekriteFaz 2
Laj 18 a 70 · Tout sèks · Mizajou Oct 1, 2026 · NCT06782490A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
Ap rekriteFaz 4
Laj 18 a 65 · Tout sèks · Mizajou Sep 30, 2026 · NCT07609719Vancomycin Study in Multiple Sclerosis (MS)
Ap rekriteFaz 1
Laj 18 a 50 · Tout sèks · Mizajou Sep 28, 2026 · NCT05539729Understanding the Impact of Meal Timing on Neurological Health in Adults With Multiple Sclerosis
Ap rekrite
Laj 18 a 64 · Tout sèks · Mizajou Sep 25, 2026 · NCT07475377A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
Ap rekriteFaz 2
Laj 18 a 70 · Tout sèks · Mizajou Sep 25, 2026 · NCT07840326A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT06433752Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT03816345Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
1 Month – 99 Years · Tout sèks · Mizajou Sep 22, 2026 · NCT00794352Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
Ap rekriteFaz 1/2
Laj 18 a 65 · Tout sèks · Mizajou Sep 21, 2026 · NCT07477639A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)
Ap rekriteEtid obsèvasyon
Laj 15 a 50 · Fanm · Mizajou Sep 21, 2026 · NCT06433765Delivery of a Culturally Tailored Exercise Training Intervention for Hispanics With Multiple Sclerosis
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07606742Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 120 · Tout sèks · Mizajou Sep 16, 2026 · NCT00001248Clinical Applications of Advanced Ophthalmic Imaging
Ap rekriteVolontè an sante akeyi
Laj 18 a 99 · Tout sèks · Mizajou Sep 16, 2026 · NCT03135327Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques
Ap rekriteFaz 2
Laj 18 a 120 · Tout sèks · Mizajou Sep 16, 2026 · NCT02784210Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Ap rekriteFaz 3
Laj 18 a 60 · Tout sèks · Mizajou Sep 15, 2026 · NCT07325292Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation
Ap rekrite
Laj 18 a 65 · Tout sèks · Mizajou Sep 15, 2026 · NCT05958381RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Sep 15, 2026 · NCT07002034Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
Ap rekriteFaz 3
Laj 10 a 17 · Tout sèks · Mizajou Sep 10, 2026 · NCT06408259A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06680037Exploring the Utility of [18F]3F4AP for Demyelination Imaging
Ap rekriteFaz 1Volontè an sante akeyi
Laj 18 a 90 · Tout sèks · Mizajou Sep 9, 2026 · NCT06999434Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 2 a 120 · Tout sèks · Mizajou Aug 31, 2026 · NCT01730131Evaluation of the Safety and Efficacy of a Full-Body Electrostimulation Garment for Individuals With Neurological and Neuromuscular Conditions That Cause Spasticity, Hyperreflexia, and Pain
Ap rekrite
Laj 18 a 75 · Tout sèks · Mizajou Aug 28, 2026 · NCT07132775Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
Ap rekriteFaz 1/2
Laj 18 a 120 · Tout sèks · Mizajou Aug 27, 2026 · NCT03109288Identifying and Characterizing Preclinical MS
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Aug 27, 2026 · NCT05787795An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
Ap rekriteFaz 1
Laj 18 a 60 · Tout sèks · Mizajou Aug 25, 2026 · NCT07224373Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.